Shi Q, Xuhong J, Luo T, Ge J, et al. PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer. Br J Cancer 2022 Nov 2. pii: 10.1038/s41416-022-02021.
PMID: 36323880